165 related articles for article (PubMed ID: 26115777)
1. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer.
Rubio-Briones J; Borque A; Esteban LM; Iborra I; López PA; Gil JM; Pallás Y; Fumadó L; Martínez-Breijo S; Chantada V; Gómez E; Quicios C; Congregado CB; Medina R; Ortiz M; Montesino M; Clar F; Soto J; Campá JM
Actas Urol Esp; 2016; 40(1):3-10. PubMed ID: 26115777
[TBL] [Abstract][Full Text] [Related]
2. Variability in the multicentre National Registry in Active Surveillance; a questionnaire for urologists.
Rubio-Briones J; Borque-Fernando A; Esteban-Escaño LM; Martínez-Breijo S; Medina-López R; Hernández V;
Actas Urol Esp (Engl Ed); 2018 Sep; 42(7):442-449. PubMed ID: 29661508
[TBL] [Abstract][Full Text] [Related]
3. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
4. Changes in Gleason score grading on serial follow-up biopsies in prostate cancer patients undergoing active surveillance.
Guijarro A; Hernández V; López B; Capitán C; Pérez-Fernández E; de la Peña E; de la Morena JM; Llorente C
Actas Urol Esp; 2015 Apr; 39(3):139-43. PubMed ID: 25305107
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
6. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know.
Rubio-Briones J; Iborra I; Ramírez M; Calatrava A; Collado A; Casanova J; Domínguez-Escrig J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; López-Guerrero JA; Salas D; Solsona E
Actas Urol Esp; 2014 Nov; 38(9):559-65. PubMed ID: 24636075
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness Criteria for Active Surveillance of Prostate Cancer.
Cher ML; Dhir A; Auffenberg GB; Linsell S; Gao Y; Rosenberg B; Jafri SM; Klotz L; Miller DC; Ghani KR; Bernstein SJ; Montie JE; Lane BR;
J Urol; 2017 Jan; 197(1):67-74. PubMed ID: 27422298
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance in low-risk prostate cancer. Patient acceptance and results.
Hernández V; Blázquez C; de la Peña E; Pérez-Fernández E; Díaz FJ; Llorente C
Actas Urol Esp; 2013 Oct; 37(9):533-7. PubMed ID: 23618513
[TBL] [Abstract][Full Text] [Related]
9. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom.
Philippou Y; Raja H; Gnanapragasam VJ
BMC Urol; 2015 Jun; 15():52. PubMed ID: 26070313
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
12. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
14. Imaging Characteristics of Prostate Cancer Patients Who Discontinued Active Surveillance on 3-T Multiparametric Prostate MRI.
Habibian DJ; Liu CC; Dao A; Kosinski KE; Katz AE
AJR Am J Roentgenol; 2017 Mar; 208(3):564-569. PubMed ID: 28075651
[TBL] [Abstract][Full Text] [Related]
15. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
[TBL] [Abstract][Full Text] [Related]
16. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
17. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
20. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.
Borque-Fernando Á; Rubio-Briones J; Esteban LM; Dong Y; Calatrava A; Gómez-Ferrer Á; Gómez-Gómez E; Gil Fabra JM; Rodríguez-García N; López González PÁ; García-Rodríguez J; Rodrigo-Aliaga M; Herrera-Imbroda B; Soto-Villalba J; Martínez-Breijo S; Hernández-Cañas V; Soto-Poveda AM; Sánchez-Rodríguez C; Carrillo-George C; Hernández-Martínez YE; Okrongly D
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):84-90. PubMed ID: 30108375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
